0
%
Medetomidine is replacing xylazine as a fentanyl adulterant, and most standard immunoassay panels were never built to catch it. Find out where your current panel has a gap, before a patient does.
Medetomidine isn’t an addition to the fentanyl supply. In the health systems tracking it, it’s a replacement, and it comes with a withdrawal syndrome that doesn’t respond to the same treatments as fentanyl or xylazine withdrawal. Clinicians who don’t know to look for it are managing a condition they haven’t been trained to recognize.
Standard FDA-approved immunoassay panels don’t cover xylazine, medetomidine, or nitazenes. A clean 10-panel result doesn’t rule out what’s actually circulating; it just means the panel wasn’t built to see it.
Source: FDA safety communication
| Yesterday's threat: Xylazine | Today's threat: Medetomidine |
|---|---|
| Roughly 100x less potent | More potent, alpha-2 selective |
| Withdrawal is manageable | Severe autonomic withdrawal |
| Not on standard panels | Not on standard panels |
Fentanyl/Xylazine Residue Test
Screens surfaces and substances before use, not just after ingestion.
Learn more →
Spiked Drink Test
Fast, discreet screening for common drink-spiking agents.
Learn more →
Accurate® Oral Fluid Device
510(k)-cleared, non-invasive collection for clinical and workplace settings.
Learn more →
Fentanyl FIA Test Kit
Quantitative, lab-grade results for clinical and forensic settings that need more precision.
Learn more →
A toxicology menu built around what's actually circulating, not a fixed legacy panel.
Rapid formats built to inform treatment or triage the same visit, not days later.
Nearly two decades as an IVD developer and manufacturer, built for scale.
Tell us what you’re screening for today. Our toxicology team will walk through where medetomidine, carfentanil, and other emerging adulterants fall relative to your current menu, and what closing that gap would look like.
Fill out the form to talk to a rep today →